Cemsidomide vs TQB3820
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Cereblon E3 ubiquitin-ligase · full Multiple Myeloma pipeline
Cemsidomide
Developed by C4 Therapeutics, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2028 · NCT07280013 (registry estimate)
No aligned efficacy figure on record for this race.
TQB3820
Developed by Sino Biopharmaceutical
NCT05020639 · Phase 1 · status unknown
This is a single-arm, open-label, non-randomized dose-escalation study designed to determine a tolerable dose rather than to test clinical benefit, with no comparator arm and no blinding. Results have not yet been posted. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
No aligned efficacy figure on record for this race.
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Cemsidomide | TQB3820 |
|---|---|---|
| PFS, median | —Not reported | —Not reported |
| OS, median | —Not reported | —Not reported |
| ORR | —Not reported | —Not reported |
| VGPR or better | —Not reported | —Not reported |
| MRD negativity | —Not reported | —Not reported |
PFS, median
- Cemsidomide
- —Not reported
- TQB3820
- —Not reported
OS, median
- Cemsidomide
- —Not reported
- TQB3820
- —Not reported
ORR
- Cemsidomide
- —Not reported
- TQB3820
- —Not reported
VGPR or better
- Cemsidomide
- —Not reported
- TQB3820
- —Not reported
MRD negativity
- Cemsidomide
- —Not reported
- TQB3820
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Cemsidomide: no structured comparison results are available for Multiple Myeloma.
TQB3820: no structured comparison results are available for Multiple Myeloma.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cemsidomide's landscape · TQB3820's landscape